Skip to main content
DWTX
NASDAQ Life Sciences

Dogwood Q3 Loss Narrows to $4.9M; Going Concern Doubt Persists With Cash Through March 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.1
Mkt Cap
$39.757M
52W Low
$0.901
52W High
$7.044
52W Position info
22% above low
Off High info
84% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

DWTX sits 22% above its 52-week low of $0.901 on elevated volume (2.2× avg).

Summary

Dogwood posted a $4.9M Q3 loss and ended September with $4.9M in cash; with the $5M October placement, runway reaches only March 2027 and management reiterates substantial going concern doubt ahead of November CINP data.


Key Events · Earnings and Guidance · DWTX

  • Q3 Loss Narrows to $4.9M

    Net loss was $4,882,942 ($0.14 per share) versus $15,744,616 ($8.20) a year earlier, a comparison inflated by the $12.0M Serpin acquired-IPR&D charge in Q3 2025.

  • Cash Falls to $4.9M

    Cash and equivalents were $4,948,266 at September 30, 2026, down from $6,524,744 at December 31, 2025, with $12.8M used in operating activities over nine months.

  • Going Concern Doubt Reaffirmed

    Management states cash plus the $5M October 2026 Sealbond placement funds operations only through March 2027, and there is substantial doubt about continuing as a going concern within one year of issuance.

  • IPR&D Impairment Risk Ahead of Data

    No Q3 impairment was taken after the $9.2M CINP charge in Q2 2026, but the $57.4M CRP IPR&D asset and $12.0M goodwill remain at risk if November 2026 CINP top-line results disappoint.


Analysis · DWTX · Life Sciences

Dogwood's third-quarter loss shrank to $4.9M from $15.7M a year earlier, but that comparison flatters the company: last year's quarter carried a $12.0M acquired-IPR&D charge from the Serpin license. The number that matters is cash — $4.9M at September 30, plus the $5M Sealbond placement that closed October 26, funds operations only through March 2027. Management states substantial doubt about the ability to continue as a going concern within a year of issuance. The company's remaining value hinges on the Halneuron CINP Phase 2b top-line data expected in November 2026; unfavorable results would likely force another impairment of the $57.4M CRP IPR&D asset and another raise. Any financing before March 2027 will be dilutive at a $1.10 share price.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DWTX was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.8M. The 52-week trading range was $0.90 to $7.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DWTX - Latest Insights

DWTX
Nov 05, 2026, 8:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $1.10 info
Change: $0 (0%) info
Market Cap: $39.757M info
DWTX
Oct 19, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $1.10 info
Change: -$0.260 (-19%) info
Market Cap: $39.757M info
DWTX
Oct 19, 2026, 8:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $1.10 info
Change: -$0.150 (-12%) info
Market Cap: $39.757M info
DWTX
Sep 14, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.10 info
Change: -$0.940 (-46%) info
Market Cap: $39.757M info
DWTX
Aug 14, 2026, 11:14 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.99
Real-time Price: $1.10 info
Change: -$0.890 (-45%) info
Market Cap: $39.757M info